Details
Stereochemistry | RACEMIC |
Molecular Formula | C28H31N3O6 |
Molecular Weight | 505.5622 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC(=O)C1=C(C)NC(C)=C([C@@H]1C2=CC(=CC=C2)[N+]([O-])=O)C(=O)O[C@@H]3CCCN(CC4=CC=CC=C4)C3
InChI
InChIKey=QZVNQOLPLYWLHQ-ZEQKJWHPSA-N
InChI=1S/C28H31N3O6/c1-18-24(27(32)36-3)26(21-11-7-12-22(15-21)31(34)35)25(19(2)29-18)28(33)37-23-13-8-14-30(17-23)16-20-9-5-4-6-10-20/h4-7,9-12,15,23,26,29H,8,13-14,16-17H2,1-3H3/t23-,26-/m1/s1
Molecular Formula | C28H31N3O6 |
Molecular Weight | 505.5622 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/16565579
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16565579
Benidipine is an orally triple L-, T-, and N-type calcium channel blocker for the treatment of hypertension and angina pectoris synthesized and developed by Kyowa Hakko Kogyo Co., Ltd. Benidipine, approved in Japan in November 1991, has become one of the three best selling CCBs and is highly useful as a potent, long-lasting antihypertensive and antianginal agent.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2095229 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2624603 |
0.32 nM [Kd] | ||
Target ID: CHEMBL4478 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10525060 |
|||
Target ID: CHEMBL2362995 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15725949 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | CONIEL Approved UseCONIEL is a calcium channel blocker and extensive clinical testing has demonstrated the sustained efficacy and effectiveness of this agent. A large body of evidence including clinical data and analyses demonstrates that CONIEL protects the heart, kidneys and brain from the effects of hypertension and angina pectoris. Launch Date1991 |
|||
Primary | CONIEL Approved UseCONIEL is a calcium channel blocker and extensive clinical testing has demonstrated the sustained efficacy and effectiveness of this agent. A large body of evidence including clinical data and analyses demonstrates that CONIEL protects the heart, kidneys and brain from the effects of hypertension and angina pectoris. Launch Date1991 |
PubMed
Title | Date | PubMed |
---|---|---|
[Effects of benidipine hydrochloride (Coniel) on blood pressure, heart rate and plasma norepinephrine concentration in spontaneously hypertensive rats]. | 1999 May |
|
Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. | 2000 Feb-Mar |
|
A case of exercise-induced acute renal failure in a patient with idiopathic renal hypouricemia developed during antihypertensive therapy with losartan and trichlormethiazide. | 2003 Jun |
|
Benidipine, a long-acting calcium channel blocker, inhibits cardiac remodeling in pressure-overloaded mice. | 2005 Mar 1 |
|
Renal-protective effect of T-and L-type calcium channel blockers in hypertensive patients: an Amlodipine-to-Benidipine Changeover (ABC) study. | 2007 Sep |
|
Blockade of T-type voltage-dependent Ca2+ channels by benidipine, a dihydropyridine calcium channel blocker, inhibits aldosterone production in human adrenocortical cell line NCI-H295R. | 2008 Apr 28 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16565579
Orally, 4 mg/day
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10525060
The oocytes expressing select Ca channels were cultured for 2 to 4 days and then subjected to electrophysiological measurement. The oocytes were placed in a small chamber perfused with extracellular solution , and Ba2+ currents through expressed channels were measured by the two-microelectrode voltageclamp method. The experimental chamber was 0.5 ml in volume, and it was perfused continuously with the extracellular solution. Typically, oocytes were clamped at a holding potential of 2100, 280, or 260 mV and depolarized to 110 mV for 200 ms every 15 s. Microelectrodes were filled with 3 M KCl, and those showing a resistance of 0.5 to 1.2 VM were used. Benidine was evaluated in concentration range of 0.1 - 100 uM, and demonstrated blocking effect with IC50 of 0.7 uM.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 17:40:17 GMT 2023
by
admin
on
Fri Dec 15 17:40:17 GMT 2023
|
Record UNII |
4G9T91JS7E
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QC08CA15
Created by
admin on Fri Dec 15 17:40:17 GMT 2023 , Edited by admin on Fri Dec 15 17:40:17 GMT 2023
|
||
|
NCI_THESAURUS |
C333
Created by
admin on Fri Dec 15 17:40:17 GMT 2023 , Edited by admin on Fri Dec 15 17:40:17 GMT 2023
|
||
|
WHO-ATC |
C08CA15
Created by
admin on Fri Dec 15 17:40:17 GMT 2023 , Edited by admin on Fri Dec 15 17:40:17 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C81680
Created by
admin on Fri Dec 15 17:40:17 GMT 2023 , Edited by admin on Fri Dec 15 17:40:17 GMT 2023
|
PRIMARY | |||
|
105979-17-7
Created by
admin on Fri Dec 15 17:40:17 GMT 2023 , Edited by admin on Fri Dec 15 17:40:17 GMT 2023
|
PRIMARY | |||
|
4G9T91JS7E
Created by
admin on Fri Dec 15 17:40:17 GMT 2023 , Edited by admin on Fri Dec 15 17:40:17 GMT 2023
|
PRIMARY | |||
|
6137
Created by
admin on Fri Dec 15 17:40:17 GMT 2023 , Edited by admin on Fri Dec 15 17:40:17 GMT 2023
|
PRIMARY | |||
|
3880
Created by
admin on Fri Dec 15 17:40:17 GMT 2023 , Edited by admin on Fri Dec 15 17:40:17 GMT 2023
|
PRIMARY | |||
|
DTXSID0022648
Created by
admin on Fri Dec 15 17:40:17 GMT 2023 , Edited by admin on Fri Dec 15 17:40:17 GMT 2023
|
PRIMARY | |||
|
m2315
Created by
admin on Fri Dec 15 17:40:17 GMT 2023 , Edited by admin on Fri Dec 15 17:40:17 GMT 2023
|
PRIMARY | Merck Index | ||
|
C061004
Created by
admin on Fri Dec 15 17:40:17 GMT 2023 , Edited by admin on Fri Dec 15 17:40:17 GMT 2023
|
PRIMARY | |||
|
100000086351
Created by
admin on Fri Dec 15 17:40:17 GMT 2023 , Edited by admin on Fri Dec 15 17:40:17 GMT 2023
|
PRIMARY | |||
|
SUB05719MIG
Created by
admin on Fri Dec 15 17:40:17 GMT 2023 , Edited by admin on Fri Dec 15 17:40:17 GMT 2023
|
PRIMARY | |||
|
656668
Created by
admin on Fri Dec 15 17:40:17 GMT 2023 , Edited by admin on Fri Dec 15 17:40:17 GMT 2023
|
PRIMARY | |||
|
CHEMBL2218858
Created by
admin on Fri Dec 15 17:40:17 GMT 2023 , Edited by admin on Fri Dec 15 17:40:17 GMT 2023
|
PRIMARY | |||
|
BENIDIPINE
Created by
admin on Fri Dec 15 17:40:17 GMT 2023 , Edited by admin on Fri Dec 15 17:40:17 GMT 2023
|
PRIMARY | |||
|
DB09231
Created by
admin on Fri Dec 15 17:40:17 GMT 2023 , Edited by admin on Fri Dec 15 17:40:17 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
METABOLIC ENZYME -> SUBSTRATE |
MAJOR
|
||
|
BINDER->LIGAND |
BINDING
|
||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
IN VITRO
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Tmax | PHARMACOKINETIC |
|
ORAL ADMINISTRATION |
|
||